


## Celecoxib-d<sub>4</sub>

<b>Cat. No.:</b>	HY-118139S
<b>CAS No.:</b>	544686-20-6
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>10</sub> D <sub>4</sub> F <sub>3</sub> N <sub>3</sub> O <sub>2</sub> S
<b>Molecular Weight:</b>	385.4
<b>Target:</b>	COX; Isotope-Labeled Compounds
<b>Pathway:</b>	Immunology/Inflammation; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Celecoxib-d <sub>4</sub> is the deuterium labeled Desmethyl Celecoxib. Desmethyl Celecoxib (compound 3b) is a selective cyclooxygenase-2 (COX-2) inhibitor (IC <sub>50</sub> =32 nM) with anti-inflammatory activities. Desmethyl Celecoxib is an analog of Celecoxib and with the optimal yield of 75%[1].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Vinay Kumar Sthalam, et al. An Integrated Continuous Flow Micro-Total Ultrafast Process System (μ-TUFPS) for the Synthesis of Celecoxib and Other Cyclooxygenase Inhibitors. RETURN TO ISSUEPREVARTICLENEXT

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA